Overview

• Precigen Q3 net loss widens significantly due to non-cash items like warrant liabilities

• PAPZIMEOS receives FDA approval, launches as first treatment for adults with RRP

• Company advances PAPZIMEOS commercialization with over 90% target institutions engaged

• Cash, cash equivalents, and investments totaled $123.6 million as of September 30, 2025

Outlook

• Company expects current cash position to fund operations to cash flow break-even

• Precigen submitted MAA to European Medicines Agency for PAPZIMEOS

• Company advancing payer and formulary access for PAPZIMEOS

Result Drivers

• INCREASED R&D EXPENSES: Research and development expenses increased by $1.0 million, or 9%, compared to the three months ended September 30, 2024

• INCREASED SG&A EXPENSES- Selling, General and Administrative (SG&A) expenses increased by $14.2 million, or 144%, compared to the three months ended September 30, 2024

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Precigen Inc is $8.25, about 51.3% above its November 12 closing price of $4.02

Press Release: ID:nPn8QL8XJa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)